Pharma Q2 Preview : Cipla to see steady qtr ; higher profit growth for DRL
Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three (...)
Site référencé: The Economic Times
The Economic Times
Trump embraces tough-on-crime mantra amid DC takeover as he and Democrats claim political wins
22/08/2025
ETMarkets Smart Talk| FII selling shifts flows to Korea, Taiwan, Japan ; DIIs remain net buyers : Dr. Poonam Tandon
22/08/2025
Classic Electrodes IPO : Check GMP, price band, issue size and other details
22/08/2025
Can Granules India leverage its strong product pipeline to offset recent profit declines ?
22/08/2025
Can betting on last year's losers lead to higher stock market returns ?
22/08/2025
Sebi proposes regulation of grey market for unlisted companies to enhance price discovery and tax revenue
22/08/2025
